Jolanta Kryczka

6PUBLICATIONS
11CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersChemotherapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jul 20, 2026
Bis-(di-4-phenyl-benzylaminethiocarbonyl)disulfide sensitizes ABCC2/ALDH3A1 overexpressing NSCLC cells to cisplatin.

|Aug 20, 2025
A preliminary bioinformatic screen to identify SRI SMC2 PSIP1 TLE4 and MSX1 as potential diagnostic and prognostic markers of osteoarthritis.

Jolanta Kryczka, Ewa Brzeziańska-Lasota, Michał Pikuła

|Nov 27, 2024
Radial Data Visualization-Based Step-by-Step Eliminative Algorithm to Predict Colorectal Cancer Patients' Response to FOLFOX Therapy.

Jakub Kryczka, Rafał Adam Bachorz, Jolanta Kryczka

|Aug 12, 2022
Isothiocyanates (ITCs) 1-(Isothiocyanatomethyl)-4-phenylbenzene and 1-Isothiocyanato-3,5-bis(trifluoromethyl)benzene-Aldehyde Dehydrogenase (ALDH) Inhibitors, Decreases Cisplatin Tolerance and Migratory Ability of NSCLC.

Jolanta Kryczka, Jakub Kryczka, Łukasz Janczewski

|Aug 27, 2021
Molecular Mechanisms of Chemoresistance Induced by Cisplatin in NSCLC Cancer Therapy.

Jolanta Kryczka, Jakub Kryczka, Karolina H Czarnecka-Chrebelska

|Apr 03, 2021
Serum Extracellular Vesicle-Derived miRNAs in Patients with Non-Small Cell Lung Cancer-Search for Non-Invasive Diagnostic Biomarkers.

Jolanta Kryczka, Monika Migdalska-Sęk, Jacek Kordiak

Pageof 1

Frequent Collaborators

5 joint publications

Jakub Mateusz Kryczka

4 joint publications

Ewa Brzeziańska-Lasota

4 joint publications

Joanna Boncela

2 joint publications

Łukasz Janczewski